CHINESE ANTIBODY SOCIETY
华人抗体协会



2023
ANNUAL CONFERENCE
CHINESE ANTIBODY SOCIETY

May 14, 2023 Cambridge, MA

Post COVID-19 Pandemic: New Frontiers and Opportunities of Antibody-based Biologics

Greetings from the Conference Co-Chairs

Dear Members and Friends of the Chinese Antibody Society,

On behalf of the Society, we extend a cordial welcome to all of you to attend our conference, "Post COVID-19 Pandemic: New Frontiers and Opportunities of Antibody-based Biologics." We are excited to see many attendees from China and around the world. The theme of the conference reflects our goal of organizing this event, and we are confident that it will provide an excellent platform to discuss the new frontiers and opportunities in antibody-based biologics.

We are thrilled to introduce two new sessions, AntibodyPlus, and Biologics CMC, alongside other presentations. We hope that these sessions will provide you with new insights into antibody-based biologics. We also hope that the Biotech Roadshow will offer many attendees the opportunity to explore new collaboration opportunities.

We also would like to draw your attention to the Poster Section, which was primarily organized by the Poster Review Committee. We received 52 poster abstract submissions, and the committee was highly impressed with the overall quality of the submissions. Unfortunately, due to space limitations, we can only exhibit two dozen poster abstracts at the conference. We encourage all attendees to view the posters during the coffee breaks. Additionally, we congratulate the winners of the top three poster abstracts, which will be orally presented at the conference. Nearly all of the submitted abstracts that passed the screening process by the Poster Review Committee will be published in the supplemental issue later this year in our Society's official journal, Antibody Therapeutics (current CiteScore Tracker: 7.3, published by Oxford University Press). We also invite all attendees, especially the authors of the poster abstracts, to submit their manuscripts to our official journal.

We are grateful for the countless evening and weekend hours devoted by the Conference Organizing Committee and the numerous volunteers. Their dedication and the generous financial support from our sponsors and corporate members have enabled us to present this one-day event. We would like to express our sincere gratitude to all the speakers, session chairs, and moderators for their contributions and support.

We strongly encourage you to take full advantage of this fantastic opportunity to immerse yourselves in the events and activities and make the most of them.

We hope you have an enjoyable and fruitful conference.

Sincerely,

The Conference Co-Chairs
Daotian Fu, PhD
Fubao Wang, PhD
Jingsong Wang, PhD
Mitchell Ho, PhD
Shouye Wang, PhD
Co-Chairs of the 2023 Annual Conference
Board of Directors, Chinese Antibody Society

SPONSORS

Title Sponsors

Dinner Sponsor

Lunch Sponsor

WIFI Sponsor

Badge Sponsor

Coffee Break Sponsor

Premium Sponsors

BEHIND THE SCENES

Board of Directors

Daotian Fu, PhD

Chairman of Board of Directors

Daotian Fu has over 20 years of experience in biologics development, and currently is President of RemeGen Co., Ltd. Prior to joining RemeGen, Dr. Fu was Vice President & Managing Director of Livzon Pharmaceutical Group, a public company listed in both China and Hong Kong stock exchanges. While at Livzon, he was also General Manager of Livzon MabPharm, Inc., a clinical stage biologics development company. Prior to joining Livzon in May 2012, Daotian was Vice President at Genzyme, where he was responsible for the quality control and analytical development of all biologics at Genzyme. Dr. Fu received his BS from Shandong University in China, and his Ph.D. from Iowa State University. He also received post-doctoral training at University of Georgia.

Dr. Fu is currently the Chairman of the Board of Directors of Chinese Antibody Society.

Fubao Wang, PhD

Dr. Wang has been working in the pharmaceutical and biotech industry for more than twenty-five years at Merck, Sanofi, Sarepta, AskBio and currently Prime Medicine as Senior Vice President, Head of Regulatory Affairs, focusing on Prime Editing technology-based product development.

Dr. Wang worked with gene editing, gene therapy, RNA therapeutics, Biologics including monoclonal antibody, and vaccine product development and directly contributed to BLA/NDA/MAA regulatory submissions and approvals of monoclonal antibody and RNA oligonucleotide products in major markets. He supported numerous INS/CTA clinical studies at all phases of Gene Therapy, RNA Therapeutics, Biologics, and vaccine development products. He also worked for the discovery and early development of preclinical candidates and life cycle management of approved commercial products.

Dr. Wang received his bachelor and master's degrees in Microbiology from Nankai University, China, Ph.D. degree in Molecular Biology from University of Heidelberg, Germany, and Postdoctoral training in Molecular Biology and Genetics at Stanford University, USA. Dr. Wang published peer-reviewed papers, reviews and book chapters and was a co-inventor of granted or filed patents.

Dr. Wang has been a member of the Board of Directors of Chinese Antibody Society since its inception and active in leading and supporting many Society's activities.

Jingsong Wang, MD, PhD

Dr. Jingsong Wang is the Founder, Chairman of the Board of Directors and CEO of Harbour BioMed (HBM, HKEX: 02142). Before establishing HBM, Dr. Wang served as the Head of China Research and Development Center and the Founding Head of Translational Medicine for Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Prior to BMS, Dr. Wang was at Wyeth (now part of Pfizer) where he served as Associate Director, and later as the Head for Translational Medicine in Inflammation and Rheumatology, Women's Health and Musculoskeletal Diseases.

Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship in the lab of Dr. Laurie Glimcher at the Harvard School of Public Health.

Dr. Wang currently is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom. Dr. Wang has published dozens of papers on various academic journals and is the author and co-author of numerous books in the field of translational medicine, inflammation and autoimmune diseases.

Mitchell Ho, PhD

Dr. Ho is a Senior Investigator, Deputy Chief of the Laboratory of Molecular Biology, and Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief for Antibody Therapeutics (Oxford University Press).

Dr. Ho's research has been focused on the development of new therapeutic paradigms for several difficult to treat cancers including liver cancer, rare cancers such as mesothelioma, and childhood cancers such as neuroblastoma. A major focus of Dr. Ho's research is on the structure and function of glypicans (e.g., GPC3, GPC2) and establishing them as new cancer-specific targets. This area of research ranges from investigation of the mechanisms by which glypicans regulate Wnt, Yap and other signaling pathways to the development of new antibody engineering technologies that lead to effective cancer therapeutics. In line with the antibody technology development, his lab has constructed shark and camel single-domain antibody phage libraries for therapeutic antibody discovery. Some of his laboratory research has direct clinical application. Clinical trials using the CAR-T cells created in his lab are ongoing for treating liver cancer and other cancers.

Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign. He completed a postdoctoral fellowship with Ira Pastan at the NIH/NCI. He was elected to the Board of Directors for the Antibody Society, the Board of Directors for the Chinese Antibody Society, and the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). He received Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, NIH Merit Award, NCI Director's Award and NCI Director's Innovation Award.

Shouye Wang, PhD

Shawn Shouye Wang was the founding president of Chinese Antibody Society, and is currently a Director of Board of Directors of the society. He is a Senior Director at WuXi Biologics. In the past 6 years at WuXi Biologics, he has been a CMC Lead for many early stage integrated CMC (Chemistry, Manufacturing, and Control) projects for IND filing and late stage projects for BLA filing with US FDA, China NMPA, and/or other countries' regulatory agencies. He has worked on diverse modalities of biologics and vaccines including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), Fc fusion proteins, and enzyme. In addition, he has been supporting WuXi Biologics' business expansion in the US, in particular the establishment of new sites in the US. He was Analytical Head of King of Prussia, PA site of WuXi Biologics in 2019. He led the Biologics CMC Leadership training program of WuXi Biologics during 2017-2010, and also led in 2022 series biologics CMC trainings for global sites in support of global expansion of WuXi Biologics. Before WuXi Biologics, he worked for Bristol-Meyer Squibb and Emergent Biosolutions. He obtained his PhD in protein chemistry from University of Science and Technology of China followed by postdoc trainings in Sweden and US.

President of Society

Bo Liu, PhD

President of Chinese Antibody Society

Dr. Bo Liu is the founding member and General Manager of Chinese Antibody Society. He is elected as the President of the Society from 2022. He is currently chairman and president of Umabs Therapeutics Inc. Prior to that, he served as the antibody discovery team leader of Matrivax corporation. Dr. Liu received his PhD in Chemistry and Molecular Biology from Peking Union Medical College, Tsinghua University. He completed the postdoc training at Harvard Medical School.

VOLUNTEERS

Yi Cao
Xi Chen
Xingcheng Chen
Zirong Chen
Wenchun Chen
Ying Cong
Mi Deng
Jijun Dong
Linlin Dong
Tianci Dong
Wanying Dou
Yitao Feng
Jean Ge
Xun Gui
Hongwei Han
Wei He
Fagen Hu
Lei Huang
Guodong Hui
Haiqun Jia
Wei Jia
Fuwei Jiang
Shikai Jin
Fang Lao
Lingxiao Li
Shichang Li
You Li
Yubin Li
Haojun Lian
Peng Lin
Bo Liu
Cui Liu
Guangbo Liu
Xiaofeng Liu
Xingdi Liu
Jing Lu
Lucy Lu
Jie Ma
Hong Pan
DongJun Peng
Haiyong Peng
Junpeng Qi
Jianyu Shang
Yufang Shao
Wuliang Si
Tian Sun
Tao Tan
Xianchun Tang
Yong Tang
Weihong Tao
Bo Tian
Zhidan Tu
Kai Wang
Long Wang
Shouye Wang
Xiang Wei
Jingyuan Wu
Siyuan Wu
Yisheng Wu
Zhinan Xia
Xiao Xiao
Xiaoban Xin
Kellen Xu
Lifei Yang
Cong Yao
Chunxiao Yu
Hongyu Zhang
Lin Zhang
Ning Zhang
Ran Zhang
Shujia Zhang
Xiangyang Zhang
Xuyao Zhang
Yanfeng Zhang
Yong Zhang
Lei Zhang
Hanchao Zhao
Shengwei Zhong
Jessica Zhou
Daocheng Zhu
Gaofeng Zhu

Executive Committee (EC) members:

Wei Jia
Peng Lin
Bo Liu
Yufang Shao
Zheng Xiao
Cong Yao
Xin Yu
Ning Zhang
Yanfeng Zhang

AGENDA

Morning Registration (7:30 AM -8:30 AM)

8:30 AM - 8:35 AM

Opening Remarks

Dr. Daotian Fu, Chairman of Board of Directors, Chinese Antibody Society; RemeGen

8:35 AM - 8:40 AM

Review of Chinese Antibody Society

Dr. Bo Liu, President, Chinese Antibody Society; Umabs Therapeutics

8:40 AM - 9:10 AM

Engineering of Antibodies to Probe and Improve Their High Concentration Properties

Dr. Paul Carter, Fellow, Genentech

9:10 AM - 9:40 AM

Development of CAR-T Cell Therapy Based on Rabbit Monoclonal Antibodies Targeting Mesothelin for Treating Solid Tumors

Dr. Mitchell Ho, Board Member, Chinese Antibody Society; Director, Antibody Engineering Program, National Cancer Institute

Coffee Break (9:40 AM - 10:25 AM)

10:25 AM - 10:30 AM

AntibodyPlus Overview

Dr. Daotian Fu, Chairman of Board of Directors, Chinese Antibody Society; RemeGen

10:30 AM - 10:50 AM

Application of "Imbalanced Bispecific Antibody" for Balanced Safety, Efficacy and Manufacturability

Dr. Yue Liu, CEO and Founder, Ab Studio

10:50 AM - 11:10 AM

mRNA-Encoded Therapeutic Antibodies: Defining Early Pharmacology in Non-Human Primates

Dr. Stefano Gullà, VP, RVAC Medicines

11:10 AM - 11:30 AM

Antibody Drug Conjugates (ADC) As Therapeutic Options: History, Resurgence and DXd Based ADCs from DSI

Dr. Tushar Garimella, Executive Director, Daiichi Sankyo

11:30 AM - 11:50 AM

AntibodyPlus Session Discussion

Session co-chair: **Dr. Daotian Fu,** Chairman of Board of Directors, Chinese Antibody Society; RemeGen

Session co-chair: **Dr. Yue Liu,** CEO and Founder, Ab Studio

11:50 AM - 12:00 PM

Lunch Sponsor Presentation

Lunch (12:00PM - 12:50PM)

Lunch Sponsored By

BIOINTRON

Afternoon Sessions

12:50 PM - 1:25 PM

New: **Poster Presentation & Best Poster Awards**

Session Chair: **Dr. Mitchell Ho,** Board Member, Chinese Antibody Society; Director, Antibody Engineering Program, National Cancer Institute

1:25 PM - 1:55 PM

Developability Assessment at Early-Stage Discovery to Enable Development of Antibody-Derived Therapeutics

Dr. Jijie Gu, CSO, WuXi Biologics

1:55 PM - 2:25 PM

Rabbit Antibodies and Their Applications in Immunogenicity / Pharmacokinetic Evaluations

Dr. Haibin Huang, Director of Antibody Discover, Yurogen

Coffee Break (2:25 PM - 3:25 PM)

3:25 PM - 4:10 PM

Introduction of Biotech Roadshow

Session co-chair: **Dr. Dandan Dong,** Chief Business Officer, Arrivent Biopharma

Session co-chair: **Dr. Zhidan Tu,** Former President, Chinese Antibody Society; Senior Director, RVAC Medicines

Biotech Roadshow-In Global For Global - Developing the Next Generation Innovative Biologics for Patients Worldwide

Dr. Mingjiu Chen, President and CEO, Biosion

Biotech Roadshow-ProundBio: Better ADCs for Better Outcomes

Dr. Zhu Chen, CSO, ProfoundBio

Biotech Roadshow-Development of Multi-targeting and Multi-functional Fc-Based Designer Biologics (FBDBTM) with Potential of Next Generation Immuno-oncology Therapies

Dr. Yi Du, Senior Director, HanchorBio Inc

4:10 PM - 4:20 PM

Biologics CMC Session Overview

Dr. Hong Li, Director, Merck

4:20 PM - 4:40 PM

Antibody Fixed-dose Combinations and Administration Strategies in Improving Patient Experience

Dr. Qingyan Hu, Associate Director, Regeneron

4:40 PM - 5:00 PM

Turning the Lights on for Commercial Continuous Biomanufacturing: From GMP Production to Facility Design

Dr. Mark Brower, Senior Director, Merck

5:00 PM - 5:20 PM

Unprecedented Post-Approval Production Cell Line and Process Changes of a Bevacizumab Biosimilar with the NMPA

Dr. Sun Chau Siu, Head of Process Development and Customer Innovation Center, Altruist Biotechnology

5:20 PM - 5:40 PM

Biologics CMC Session Discussion

Session chair: **Dr. Hong Li,** Director, Merck

Session chair: **Dr. Shouye Wang,** Board Member, Chinese Antibody Society

5:40 PM - 5:45 PM

Closing Remarks

Dr. Mitchell Ho, Board Member, Chinese Antibody Society; Director, Antibody Engineering Program, National Cancer Institute

Dinner Reception (starts at 7:00 PM)

Dinner Sponsored By

SPEAKERS & SESSION CHAIRS

Daotian Fu

Chairman of Board, CAS; President, RemeGe

Daotian Fu has over 20 years of experience in biologics development, and currently is President of RemeGen Co., Ltd. Prior to joining RemeGen, Dr. Fu was Vice President & Managing Director of Livzon Pharmaceutical Group, a public company listed in both China and Hong Kong stock exchanges. While at Livzon, he was also General Manager of Livzon MabPharm, Inc., a clinical stage biologics development company. Prior to joining Livzon in May 2012, Daotian was Vice President at Genzyme, where he was responsible for the quality control and analytical development of all biologics at Genzyme. Dr. Fu received his BS from Shandong University in China, and his Ph.D. from Iowa State University. He also received post-doctoral training at University of Georgia.

Dr. Fu is currently the Chairman of the Board of Directors of Chinese Antibody Society.

Paul Carter

Fellow, Genentech

Dr. Paul Carter is a Genentech Fellow in the Antibody Engineering Department at Genentech. In 2022 he was elected to the US National Academy of Engineering “for creating novel approaches to discovering and developing life-saving antibody therapeutics, including bispecific antibodies”. Paul co-initiated the humanization of antibodies at Genentech with a novel and patentable method. This technology has been utilized for the discovery of 9 approved antibody products that have been used to treat millions of patients worldwide. Paul and collaborators created ‘knobs-into-holes’ technology widely used in generating bispecific antibodies including two approved products. He also developed a common light chain technology used by others in generating bispecific antibodies including one approved product. He invented technology for high-titer expression of antibody Fab fragments in E. coli used for one approved antibody product. Paul has authored or co-authored 119+ scientific publications that together have been cited 25,000+ times. He is an inventor or co-inventor on 51+ issued US patents. He has co-organized 22 international conferences on antibody engineering and antibody therapeutics. He has delivered 128 conference presentations and invited lectures including 16 keynote presentations. Paul received a B.A. in Natural Sciences from Cambridge University and his Ph.D. under Sir Greg Winter, Ph.D. at the MRC Laboratory of Molecular Biology in Cambridge. He was a Postdoctoral Fellow with Dr. Jim Wells at Genentech. Paul has ~37 years of biotechnology experience including at Genentech, Immunex, Amgen, Seattle Genetics and VLST. His professional experience includes heading the postdoctoral programs at Genentech, Immunex and Amgen. Additionally, he has served on the Board of Directors of the Antibody Society as President.

Mitchell Ho

Board Member, CAS

Senior Investigator, Deputy Director, the Laboratory of Molecular biology; Director, Antibody Engineering Program, National Cancer Institute, NIH.

Dr. Ho is a Senior Investigator, the Deputy Chief of the Laboratory of Molecular Biology, the Head of the Antibody Therapy Section, and the Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He received his Ph.D. from the University of Illinois at Urbana-Champaign. Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his laboratory work is on the characterization of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the fundamental mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapeutics. His laboratory also established mammalian cell surface display, developed rabbit monoclonal antibodies, and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The immune therapeutics such as CAR-T cells based on his research are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers.

Dr. Ho serves on the Board of Directors for the Antibody Society, the Chinese Antibody Society, and the Foundation for Advanced Education in the Sciences (FAES). Dr. Ho received many awards including the Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, Dr. Francisco S. Sy Award for Excellence in Mentorship at HHS, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, and NCI Director's Innovation Award.

Yue Liu

CEO and Founder, Ab Studio

Dr. Yue Liu has more than 20 years of experience in therapeutic antibody research and development and more than ten years of experience in computer aided therapeutic antibody design. She has led multiple therapeutic antibody programs on various diseases, including cancer, thrombosis, AMD and protein aggregation diseases. In 2017, Dr. Liu founded Ab Studio Inc. and led the ABS team developed several unique technology platforms: 1) "Imbalanced" bispecific antibody platform; 2) "Serial" internalizing antibody platform; 3) "Catalytic" antibody platform and 4) "Humanized" llama VHH phage display platform. Aided with these platforms, Ab Studio developed GB261, a Fc enabled, CD3 detuned CD20/CD3 TCE and GB263T, an EGFR/c-Met tri-specific antibody. Both of which have been moved forward to clinical trial I/II stage by our partner Genorbio. Dr. Liu is holding Ph.D. in microbiology and infectious diseases from Universite de Sherbrooke, Canada, M.Sc. in internal medicine from Soochow University, China and B.Sc. in biology from Nanjing University, China. She is the author and co-author of multiple scientific publications and inventors of multiple patent and patent applications.

Stefano Gullà
VP, RVAC

In his current role as VP of Biology and Therapeutics at RVAC Medicines, Stefano leads discovery and development of an innovative pipeline of mRNA encoded protein therapeutics. In previous leadership roles at Repertoire Immune Medicines, Agenus and Pfizer, Stefano contributed to discovery and development of biotherapeutics for immuno-oncology, autoimmunity, and rare diseases. In 2016, Stefano founded Abcuro Inc. and served as the President CEO/CSO until 2020 developing first-in-class antibody therapeutics for autoimmune and immuno-oncology indications.

Tushar Garimella
Executive Director, Daiichi Sankyo

Dr. Tushar Garimella has more than 15 years of experience in the Pharmaceutical Industry focused on the Clinical Pharmacology and Pharmacometrics aspects of drug development.

Dr. Garimella's education includes a BPharm from the Bombay College of Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore. He started his industry career in Abbott Laboratories followed by Bristol-Myers Squibb. Currently, Dr. Garimella is an Executive Director and oncology portfolio lead in the Quantitative Clinical Pharmacology department at Daiichi Sankyo Inc.

Dr. Garimella has wide ranging experiences in both exploratory development and late-stage development across multiple therapeutic areas, including neuroscience and pain, oncology and immunology, virology and cardiovascular health. He has worked on multiple registrational projects, supporting submissions for FDA, EMA, PMDA, China CDE and Rest of the World.

Dr. Garimella has published more than 30 manuscripts and 50 abstracts in peer reviewed journals and international conferences throughout his career.

Jijie Gu
CSO, WuXi Biologics

Dr. Jijie Gu, aged 57, serves as Executive Vice President and Chief Scientific Officer of WuXi Biologics. Dr. Gu brings more than 20 years of drug research and development expertise and extensive management experience to the firm. He has significant expertise in target discovery, therapeutic design, protein engineering, preclinical drug discovery and early clinical development.

Prior to joining WuXi Biologics, Dr. Gu served as a function head at AbbVie Cambridge Research Center, where he led target validation and lead discovery in AbbVie Immunology for both small and large molecule drugs. Before that, he was a function head of Oncology Biologics in Global Biologics at AbbVie Bioresearch Center.

While at Abbott/AbbVie, Dr. Gu made critical contributions to building antibody platform technologies. He led the construction of novel biologics platform technologies, including Fc engineering, ADC technology, TCR technology, bispecific and multispecific antibody technologies and T cell engagers. He also led projects in multiple therapeutic areas relating to oncology, immunology, immuno-oncology, metabolic disease, neuroscience and ophthalmology, and contributed broadly to AbbVie Biologics portfolio and delivered several New Biological Entities (NBEs) into clinical development.

Throughout his extensive career, Dr. Gu has co-invented more than 20 filed and issued U.S. patents and has coauthored 40 publications. He currently serves on the editorial boards of the peer-reviewed journals Antibody Therapeutics.

Dr. Gu obtained his Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical School. He received postdoctoral training in Tumor Immunology at the Dana Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, and in Cancer Cell Biology at the Harvard School of Public Health.

Haibin Huang
Director of Antibody Discovery, Yurogen

Dr. Haibin Huang is currently director of antibody discovery at Yurogen Biosystems LLC, a subsidiary of ABclonal Technology. Dr. Huang is responsible for R&D, execution, management and support of CRO projects based on Yurogen's SMab® single B cell platform. He is also responsible for supervising junior scientists and research associates at Yurogen. Prior to joining Yurogen, Dr. Huang worked as a post doc and an instructor at UMass Chan Medical School, where he developed novel beta-glucan particle-based vaccine platform that can stimulate both robust cellular and humoral immune responses and several anti-fungal vaccines utilizing the newly developed beta-glucan particle-based vaccine platform. Dr. Huang obtained his Ph.D. in the field of Microbiology and Immunology from the Ohio State University, M.S. in Genetics and B.S. in Microbiology from Fudan University.

Mingjiu Chen

President and CEO, Biosion

Dr. Mingjiu Chen, PhD, is currently the founder and CEO of Biosion Inc. Dr. Chen has 30+ years of broad experience in biomedical research, biologics R&D, and corporate operations as an entrepreneur. Before establishing Biosion, Dr. Chen served as Senior Director of Monoclonal Antibody Operations at SDIX, Inc., where he led the team responsible for innovative antibody discovery for leading biotech and pharmaceutical companies. Before joining SDIX, Dr. Chen worked as Senior Scientists at Abbott Laboratories (now AbbVie), where he made critical contributions for several innovative biologic programs and for developing high-throughput high-content high-efficiency hybridoma platform. Prior to AbbVie, he was responsible in developing innovative antibody therapeutics to novel targets at Lexicon Pharmaceuticals. Dr. Chen has owned 20+ global patents of innovative antibodies, about 10 innovative therapeutic candidates are currently in different stages of clinical trials.

Zhu Chen

CSO, ProfoundBio

Zhu is currently the Chief Scientific Officer at ProfoundBio. Prior to joining ProfoundBio in early 2021, Zhu served as the Global Medical Lead at Daiichi Sankyo responsible for medical strategy and launch preparation for datopotamab deruxtecan and additional compounds in heme and solid tumors, and the Global Medical Lead at Celgene overseeing medical and launch activities for assets in myeloid malignancies. Earlier in her career, Zhu spent 12 years at Merck Research Laboratories with increasing responsibilities including discovery team lead and early development team lead. Zhu received her Bachelor degree in Biochemistry & Molecular Biology from Beijing University and Ph.D. in Pharmacology & Genetics from the University of Texas Southwestern Medical Center at Dallas, followed by a post-doctoral training in diabetes and obesity at the Rockefeller University. She has published more than 30 peer reviewed articles and is a co-inventor of multiple patents on agents targeting various diseases.

Yi Du

Senior Director of Business Development, HanchorBio

Dr. Yi Du is currently the Senior Director of Business Development of HanchorBio Inc., a global biotechnology company pioneering the development of next-generation immunotherapies. He is currently taking care of the business development activities across China and US.

Dr. Du has over 17 years of experience in the pharmaceutical industry. He has led over 20 projects at various stage of development for both small molecule and large molecule products. Prior to joining HanchorBio, Dr. Du has worked in different roles in business development including search and evaluation and alliance management for several pharmaceutical companies. Dr. Du received his B.S. from Peking University and Ph.D. in Chemistry from University of Illinois at Urbana-Champaign. He obtained his MBA in Finance and Healthcare from Northeastern University.

Hong Li

Director, Merck

Dr. Hong Li is currently a Director in the Biologics Process and Research Development organization, Merck & Co., Inc located in Kenilworth, New Jersey. Dr. Li obtained her Ph.D. in Biochemistry at Virginia Tech in 2002. She then continued her postdoctoral training in protein biochemistry, expressing, purifying and characterizing different recombinant proteins, including complex membrane and fatty acid transporter proteins. In 2007, she joined Schering-Plough now Merck. She has held positions with increasing responsibilities at Merck for about 15 years. She and her group focus on downstream process development and building integrated control strategies for therapeutic proteins.

Qingyan Hu

Associate Director, Regeneron

Qingyan Hu received her PhD in Chemistry from the University of Toronto in 2005. After 2-year postdoc, she joined Roche Global Formulation Research in 2007. At Roche, Qingyan has led formulation research projects on peptides, siRNA and small molecules. In 2013, Qingyan joined Formulation development group at Regeneron Pharmaceuticals. She is currently an associate director at Regeneron, leading multiple monoclonal antibodies and genetic medicines formulation and drug product development projects in early and late stage clinical trials. Qingyan's research area includes protein formulation and stability, biophysical characterization, compatibility and in-use stability for clinical administration, etc. Qingyan is also an active member of biopharmaceutical industry forums and professional societies.

Mark Brower

Senior Director, Merck

Mark Brower is currently the lead of the Continuous and Expression Technologies group within Enabling Technologies, Process Research and Development Department at Merck & Co., Inc. There, he is responsible for leading a team of cross-functional scientists investigating novel upstream, downstream, and chemistry initiatives towards a low-cost therapeutics production platforms including perfusion cell culture, continuous biomanufacturing and flow chemistry. Prior to this, Mark has developed purification processes for both natural product secondary metabolites and small molecule enzymatic biotransformations. Mark earned his BS in Chemical Engineering from The Pennsylvania State University, and a PhD in the same field from Cambridge University.

Sun Chau Siu

Head of Process Development and Customer Innovation Center, Altruist Biotechnology

Dr. Sun Chau Siu is Head of Process Development and the Customer Innovation Center at Altruist Biotechnology. Dr. Siu has broad responsibilities overseeing project management, CMC strategy and compliance, and technical innovation. He has over 23 years of international experience in the biopharmaceutical industry, with rich knowledge in GMP manufacturing, validation, MSAT, tech transfer, regulatory, CMC development, and process development. Before Altruist, he had worked at Genentech (USA). His professional experience also includes Roche (Singapore), Pfizer (UK), and Sanofi Pasteur (Canada). Among his experience, he played critical roles in the start-up of two biologics facilities, led multiple process tech transfers, successfully obtained health authority application approvals, and supported numerous health authority GMP/PAI/PLI inspections.

Dr. Siu has a Ph.D. and MSc in Biochemical Engineering from University College London, UK, and a BSc (Hons) in Biochemistry and Chemistry from The University of British Columbia, Canada. He also obtained an executive MBA from Rutgers University, USA, and is a certified Project Management Professional (PMP).

Dandan Dong

Chief Business Officer, ArriVent Biopharma

Dr. Dandan Dong is the Chief Business Officer of ArriVent Biopharma. Dr. Dong has more than 15 years' experience in global healthcare investment. Before joining ArriVent, Dr. Dong was the Managing Director of Vivo Capital, and the managing member of General Partner of Vivo Capital PANDA Fund & Innovation Fund II. Over her career she has led multiple successful investments in innovative drugs in both the U.S. and Greater China Market. She has been focusing on cross border opportunities, incubated multiple biotech companies with cross border theses. Most recently, she was the Chief Business Officer, Executive Board member of Visen Pharmaceutical, a joint venture between Ascendis Pharma (NASDAQ: ASND). As a founding member, she led the effort of in-licensing core pipelines, designing corporate strategy, recruiting key management, financing and was the chair of Joint Collaboration Committee. She co-founded RareStone Group, to build the first rare disease ecosystem in the Greater China, served on the board, the transaction committee and financing committee.

Zhidan Daniel Tu

Former President, CAS;
Senior Director, RVAC

Zhidan Daniel Tu is Senior Director of Business Development and Operations at RVAC. Before joining RVAC, he was Director of Business Development at Legend Biotech. He led end-to-end licensing activities and managed alliances with key partners. From 2011 to 2017 he served several scientific, management and commercial roles at GenScript, including Director, Head of Corporate Development of SMAB Bispecific Antibody Platform, Head of Global Commercial Team of Discovery Biology Business Unit, Scientific Liaison of US Eastern Region and Senior Scientist of Antibody Department.

Dr. Tu received his PhD of Immunology from joint training of Case Western Reserve University and West China Hospital of Sichuan University, and bachelor's degree of Biotechnology from Life Science College of Sichuan University.

CAREER CENTER

About Career Center of Chinese Antibody Society

To better serve the global antibody community, Chinese Antibody Society (CAS) launched a Career Center website: https://chineseantibody.net with focus on job posting, resume submission, and career development. In addition to offering FREE registrations at the website, CAS also offers the following services, all FREE of charge.

1. **Weekly** collecting all the job posts at the above website and sharing the jobs at 12 Wechat groups of CAS (about 4,000-5,000 members).

2. **Weekly** selecting at least one job from the website and advertising it at LinkedIn account of our society (over 7,000 followers)

3. Approximately **quarterly** sharing the collected jobs from the Career Center website with our society's Wechat account (over 30,000 followers).

Many companies and organizations have registered at the website and posted jobs, We now welcome companies and individuals to take advantage of these free services.

You are welcome to visit the website and register NOW at: https://chineseantibody.net or scan the following QR code.

Follow us at Chinese Antibody Society:
LinkedIn: https://www.linkedin.com/company/chineseantibodysociety
Wechat: 华人抗体 (ID: Chinese_Antibody)

YUROGEN
A subsidiary of ABclonal

Quality Antibodies Facilitate Your Discovery

Yurogen Biosystems is an international biotechnology company founded in Boston, Massachusetts in 2014, dedicated to the discovery and development of monoclonal antibodies. In 2018, we expanded our CRO services to the East Asian market by establishing a branch in Wuhan, China. To further extend our global coverage, we merged with ABclonal Science Inc., a growing provider of biological reagents and services, in 2021. Our state-of-the-art SMab™ platform, a single-B-cell-based monoclonal antibody development technology, has enabled us to successfully develop a variety of antibodies, including rabbit, llama, and human monoclonal antibodies, providing antibody-based solutions for scientific research, in vitro diagnostics, and antibody-related drug development applications. Through innovative research and development, Yurogen Biosystems has become a preeminent leader in the field of customized antibody discovery, engineering, and production, serving various leading biotechnology and pharmaceutical companies in the U.S. and abroad.

EXTENSIVE
- Multiple Species: Rabbit, Camelid, Human etc.
- Multiple Applications: Therapeutic, Anti-idiotype, Diagnostic etc.

EFFICIENT
- Functional Clone Identification in Early Stage
- High Throughput Screening & Positive Rate



ECONOMIC
- Flexible Customization Service & Step-wise Billing
- No Milestone/Royalty Fee

EXPERIENCE
- First Commercialized Single B-Cell Platform for mAb Discovery
- 2000+ Projects Delivered by Seasoned Technical Team

One Stop Antibody Discovery

Single B cell mAb discovery:
- Rabbit monoclonal antibody
- Camelid nanobdoy
- Human monoclonal antibody

Antibody Engineering:
- Antibody humanization
- ScFv design and engineering
- Antibody class switch

Antigen design and immunization:
- Antigen design and expression
- VLP immunization
- Cell immunization
- DNA/mRNA immunization

Other Services:
- Recombinant mAb manufacture
- Stable cell line construction
- Affinity ranking & measurement
- Biological assay development

www.yurogen.com
customer@yurogen.com

1 Innovation Drive, Suite 420
Worcester, MA 01605, United States

BIOINTRON

About Biointron

Biointron is a leading CRO specializing in antibody related services. With ISO 9001:2015 certification and over 700 employees, Biointron is your trusted and reliable supplier for recombinant antibody expression with a fast turnaround time in just two weeks. We had delivered tens of thousands of recombinant antibodies/proteins to over 1,000 biotech/biopharma companies worldwide. We offer various antibody discovery platforms, antibody humanization and affinity maturation services, pairing with a range of downstream in-vitro assays for verification. We also provides a comprehensive portfolio of catalog products, including overexpression cell lines, research-grade target positive antibodies and isotype negative antibodies, all subject to rigorous experimental verification and quality control.

Services We Offer

- Antibody Production
- CHO-K1 Stable Cell Line
- VHH Antibody Discovery
- Single B Cell Screening
- Affinity Maturation
- Antibody Humanization
- Over Expression Cell Line
- Isotype Control/ Target positive antibody

Enter a lucky draw to receive a surprise gift

Scan Me to Enter Raffle

www.biointron.com
info@biointron.com
+1 (732) 515-4766
New Jersey, USA | Shanghai, China



At Biokin, we take pride in being pioneers in the field of antibody development. For over 26 years, we have been dedicated to developing innovative antibody-based therapies and providing essential medicines to patients in need.

Through our proprietary and fully integrated biological drug development platform, we are able to execute discovery and development that delivers bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) to treat patients with solid tumor and hematologic indications. Our focus on targeted and effective therapies is at the core of everything we do.

We are proud to have several assets in various stages of clinical trials and a robust preclinical pipeline of potential cancer therapeutics. Our cutting-edge biologics development represents a significant contribution to the advancement of cancer treatments, and we are committed to bringing novel cancer therapies to patients in need.

We are driven by our passion for improving patient outcomes and our dedication to advancing cancer research. Our innovative approach and unique therapies have the potential to make a significant impact in the fight against cancer, and we are honored to be at the forefront of this crucial work.



百利药业
BIOKIN PHARMACEUTICAL

Nona Biosciences

Empowering Global Biotherapeutic Innovation

Nona Biosciences is a global biotechnology company committed to provide innovative technologies and integrated discovery solution for biotech and pharmaceutical companies. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice®

Clinically Validated Fully Human Antibody Platforms

- Global IP protection with **65+** granted patents
- Validated by **50+** industry and academic partners
- Applied in **200+** discovery programs
- **14+** projects entered clinical stage
- High efficiency, High quality, High success rate

HCAb PLUS ™

Next-Generation Therapeutic Modalities



Antibody Discovery Solution

A one-stop solution for therapeutic antibody discovery, engineering and development



For more information:
BD@nonabio.com

www.nonabio.com



ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world' s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as **A**CROBiosystems, **b**ioSeedin, **C**ondense Capital, and ACRO**D**iagnostics.

ACROBiosystems' brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

AlpalifeBio

Nanobody Discovery & GPCR Service

Dedicated to Support Your Novel NanobodyVHH and GPCR-targeted Drug Development

A — Customized Nanobody Discovery Service

- Alpaca Immunization
- Library Construction
- Library Screening
- Affinity Maturation
- Humanization

B — Alpaca Anti-Tag VHH Products

- Anti-Flag VHH Beads
- Anti-GFP VHH Beads
- Anti-MYC VHH Beads
- Anti-HA VHH Beads
- Anti-mCherry VHH Beads
- Anti-MBP VHH Beads
- Anti-GST VHH Beads

C — Recombinant Protein Production

- Bacterial Expression
- Yeast Expression
- Insect Cell Expression
- Mammalian Cell Expression
- GPCR Drug R&D Service
- GPCR Drug Development Support

AlpalifeB Inc.
Toll-free Phone: 1-413-399-9518;
Fax 1-617-336-7451
Office Phone: 1-617-383-9901 Ext 800.
Email: info@alpalifebio.com
Website: www.alpalifebio.com
Address: 299A Washington Street, Woburn, MA 01801 USA

GemPharmatech

GemPharmatech

One Stop Solution for Biomedical Research

World's Largest Collection of Genetically Engineered Mouse Models (GEMMs)

Our professional and experienced team of scientists provide top quality service for our clients, while our extensive mouse resources offer humanized mice, immunodeficient mice, and disease models, which support a wide range of studies in the fields of oncology, autoimmune, neurodegenerative, metabolic and rare diseases. GemPharmatech is committed to expediting biomedical discovery and drug development.

HIGH-QUALITY SERVICES

Advanced technology platform for custom model generation
Professional drug screening service platform
Germ-free and translational microbiome research platform

LARGEST MODEL RESOURCES

Largest GEMM library with **22,000+** models
6,000 new GEMM generation capacity/year
Best technology for your needs with 20+ years of experience (CRISPR/Cas9, Transgenic)

LEADING CAPABILITIES

14 years of AAALAC accreditation
30,000+ m² non-GLP experimental facilities
230,000+ SPF and germ-free mouse housing facilities
Global presence with 7 operational sites in China and the US

GemPharmatech | sales@gempharmatech.us | +1 888 899 5899 | https://en.gempharmatech.com

GenScript PROBIO

Innovative Antibody Drug Discovery Platform

Customized one-stop discovery services for mAb, sdAb, bsAb, ADC and CAR

Antibody lead generation
- Hybridoma discovery
- Single B cell discovery
- Human Fab library
- Transgenic mice platform

Antibody lead optimization
- Antibody humanization
- Affinity maturation
- Fc engineering
- Developability optimization

***In vitro* bioassay**
- ADCC,CDC&ADCP assay
- Customized reporter gene assay
- Primary immune cell assay
- Antibody internalization assay

***In vivo* pharmacology**
- *In vivo* efficacy
- Pharmacokinetics study
- Toxicology study
- Biomarker testing and bioanalysis

Antibody reagent service
- Affinity measurement
- Anti-idiotypic antibody discovery
- PK/ADA ELISA kit development
- Developability assessment

Biologics CMC & Clinical Manufacturing Services

One-stop CDMO services to accelerate drug development

01 Stable cell line development
02 Host cell commercial license
03 Upstream process development
04 Downstream process development
05 Analytical method development
06 GMP clinical manufacturing
07 Regulatory quality system

GenScript ProBio offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine and antibody protein drug, aiming to accelerate drug development for customers.

www.genscriptprobio.cn

HUABIO

Hangzhou HuaAn biotechnology Co.Ltd (referred to as "Huabio") was founded in 2007, HUABIO is dedicated to developing curated, high-quality antibodies that advance innovation. Huabio provides a wide range of products that covers recombinant rabbit monoclonal antibodies, mouse monoclonal antibodies, alpaca antibodies, ADC drug small molecule detection antibodies, ELISA and matched antibody pairs, and recombinant proteins. Our customed service including antibody development, bulk antibody production, antibody conjugation, and hybridoma production.

> 12359+ products
> 3000+ research subjects
> 40+ countries
> 1,000,000+ scientists

Huabio's HiMab™ technology is able to generate a large number of high-quality rabbit mAbs within three months. Our rabbit mAb discovery technology involves sorting, cloning of rabbit B cells, and high throughput (HTP) antibody production. HiMab™ platform generate high-specificity, high-affinity mAbs towards a wide range of difficult targets such as small molecules, Ab drugs, and protein post-translational modifications (PTMs) .

We're passionate about the accuracy, efficiency, and consistency of our products.

OUR CORE TECHNOLOGY

www.huabio.com/www.huabio.cn

益诺思 INNOSTAR

InnoStar Provides One-stop Service from Nonclinical to Clinical Translation

Services

Nonclinical Safety Evaluation

- Pharmacology including Safety Pharmacology
- Pharmacokinetics/Toxicokinetics(ADME)
- General Toxicity
- Genetic Toxicity
- Carcinogenicity
- Developmental and Reproductive Toxicity
- Special Toxicity

IND-Enabling Package

- Pharmacology Studies
- PK/TK Studies (ADME)
- General Tox Studies (Up to 4W)
- Genotoxicity Studies
- Others as needed

DMPK & Bioanalysis

- Bioanalytical method development and validation
- Bioanalysis(Preclinical and Clinical)
- Immunogenicity
- Biomarkers
- Modeling and Simulation

Regulatory Services

- Consulting Service
- Translation and Dossier preparation for IND/NDA Filling
- Regulatory Support for IND/NDA Filling

Talent team

6 NMPA CDE New Drug Evaluation Experts	4 NMPA & CNAS GLP Senior Inspectors	5 Members of NMPA ICH/ National Guidance Expert Groups	12 DCSTs	4 China QA GLP Qualification
2 Canadian Laboratory Animal Veterinary Qualification	3 US AAALAC Inspection Specialists	3 US SQA RQAP-GLP Certificates	1 International Academy of Toxicolodic Pathology (IATP) Fellow	1 Japanese Toxicologic Pathologist Japanese Veterinary Pathologist

Certication

- NMPA GLP Certification 2010/2015/2019/2022/2023
- OECD GLP Certification (Netherlands) 2012/2015/2017/2019
- U.S. FDA GLP Inspections 2014/2018
- AAALAC Certification 2011/2014/2017/2020/2023
- U.S. CAP Certification 2015/2017/2019/2022

MabPlex 迈百瑞

Experienced World-class CDMO for Biopharmaceutical Clients

MabPlex International Co., Ltd. is committed to providing global biopharmaceuticals with one-stop customized service from concept to commercial manufacturing for mAb, bispecific antibody, fusion protein, and ADC therapeutics.

One-stop Service

Service from cell-line development to commercialization

Pre-clinical	IND	Phase I	Phase II	Phase III	BLA	Commercialization
Pre-clinical Development	Scale-Up/Process Optimization		Process Characterization	Process Validation	Continued Process Verification	

Customization

Customized service with high quality and speed

The protocol shall be configured in strict accordance with the laws and regulations of the listing application area and the R&D stage of the user, taking into account the production cost and cycle, so as to strive for sufficient time for drug listing application.

Manufacturing

Multi-scale antibody production lines from 50L to 2000L(over a dozen) from 3 different mainstream brands, and ADC conjugation scale up to 150L.

Compliance

Quality system in full compliance with the GMP standards of NMPA, the U.S. FDA, EMA and Japan, etc.

HEADQUARTERS
No. 60, Middle Beijing Road
Yantai, China (Shandong)
Pilot Free Trade Zone

SAN DIEGO
10210 Campus Point Drive
Suite 100
San Diego, CA 92121

MabPlex International Co. Ltd.
mabplexinc.com
info@mabplexinc.com
+1-800-925-3608

NBbiolab

Single domain antibody R&D Center

www.nbbiolab.com

+86 4008677715 service@nb-biolab.com

Nbbiolab is one of the well-recognized experts who are committed to developing novel antibodies with desired specificity and affinity for research, diagnostic, or therapeutic applications. With years of experience, our scientists have developed advanced sdAb discovery platforms based on phage display technology, yeast surface display technology, and protein engineering. NBbiolab is pleased to offer the best professional sdAb-related services to satisfy each demand from our clients.

Protheragen

Protheragen Actively Seeks Collaborations and Recruits Talents

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. We serve as a global business development partner for biotech/pharmaceutical companies and have built close relationships with many investment companies. To further our development, part of our strategies require us to constantly seek high-quality novel drug research and development programs that are open to collaboration opportunities.

Relying on strong industry resources and connections built up throughout the years, Protheragen welcomes partnerships in the following structures:

- **Equity Investment**
- **Intermediary Service**
- **Project Incubation**

As a non-traditional pharmaceutical company, Protheragen is searching for talented and self-motivated senior research scientists to fill the new space with innovative technologies and enthusiastic attitude. We will:

- **Help you become an entrepreneur**
- **Offer a competitive salary and benefit package**
- **Provide work visa sponsorship**

Tel: 1-516-765-9461
E-mail: info@protheragen.com
Address: Room 1, 2200 Smithtown Avenue, Ronkonkoma, NY 11779-7329, USA

Get in Touch
www.protheragen.com

Purolite®
An Ecolab Company

Purolite is a leading manufacturer of quality affinity, ion exchange, adsorbent and specialty high-performance resins. Praesto® bioprocessing products aim to improve the accessibility and availability of cutting-edge antibody therapeutics worldwide, which are typically used to treat, extend life and improve quality of life for patients with cancer, arthritis, diabetes and many other conditions. These agarose-based chromatographic resins are key raw materials for the downstream processing of antibodies and recombinant proteins and are trusted by many of the leading biopharmaceutical manufacturers and CMOs. Praesto resins are currently implemented in FDA-approved commercial manufacturing processes and hundreds of clinical trials worldwide.

The Chinese Antibody Society
955 Massachusetts Ave #276
Cambridge, MA 02139, USA

Email:management@chineseantibody.org
Website: www.chineseantibody.org
LinkedIn: www.linkedin.com/company/chineseantibodysociety/
Journal: academic.oup.com/abt
Facebook: https://www.facebook.com/ChineseAntibody/